dutasteride

Overview

Dutasteride is a dual 5-alpha reductase inhibitor (targeting SRD5A1 and SRD5A2) that blocks conversion of testosterone to dihydrotestosterone (DHT). It is used clinically for benign prostatic hyperplasia (BPH) rather than as a cancer treatment. In the corpus it appears as a background medication noted for one patient who received it for BPH prior to prostate cancer profiling.

Evidence in the corpus

• One patient in the MSK-IMPACT prostate cancer cohort had previously received dutasteride for benign prostate enlargement; this patient’s tumor was nonetheless profiled and included in disease-state enrichment analyses PMID:28825054.

Resistance mechanisms

(No resistance mechanisms described in this corpus.)

Cancer types (linked)

• PRAD — prostate adenocarcinoma; dutasteride noted as prior BPH medication in one patient in a pan-prostate cancer sequencing study PMID:28825054.

Sources

• PMID:28825054 — Abida et al. 2017, MSK-IMPACT pan-prostate cancer genomic profiling; dutasteride appears as background prior therapy in one patient.

This page was processed by entity-page-writer on 2026-05-15.